Revolution Medicines' Zoldonrasib (RMC-9805) Phase 1 Trial Results

Revolution Medicines (RVMD) presented the latest data from the Phase 1/1b trial of zoldonrasib, a RAS(ON) G12D covalent inhibitor, at this conference. The trial involved 27 patients with G12D-mutated non-small cell lung cancer (NSCLC) who had failed prior treatments, and the results showed an objective response rate (ORR) of 52% and a median progression-free survival (mPFS) of 11.1 months. Considering that the mPFS for conventional chemotherapy is only about 4 months, this represents a significant improvement in treatment efficacy. This demonstrates that a new mechanism that directly targets the active RAS(ON) protein in cancer cells is clinically very effective, and it is expected to strengthen Revolution Medicines' position in the lung cancer field, following the pancreatic cancer field.

Merck's Next-Generation Bispecific Antibody MK-2010 Enters the Race

Merck (MRK) has released the first human clinical data for MK-2010 (LM-299), a bispecific antibody targeting PD-1 and VEGF, which was acquired from LaNova Medicines in 2024. In an early clinical trial involving PD-L1-positive NSCLC patients, 55% of patients in the low-dose group and 44% in the high-dose group showed a response to the drug. This is similar to the level of ivonescimab from Summit Therapeutics (SMMT) or pumitamig from BioNTech (BNTX), but it is said that it does not yet have a distinct advantage. Nevertheless, this trial clearly demonstrates Merck's strong will to secure a competitive position in the rapidly growing bispecific antibody anticancer drug market in preparation for the expiration of Keytruda's patent.

Nuvalent and Nuvation Bio's ROS1 Therapies Compete

The competition between Nuvalent (NUVL) and Nuvation Bio (NUVB) for their next-generation tyrosine kinase inhibitors (TKIs) in the ROS1-mutated NSCLC market has intensified. Nuvalent presented clinical results for zidesamtinib (NVL-520), which is scheduled for a decision date (PDUFA), showing that it achieved an objective response rate of 41% and 47% in patients who had previously taken Augtyro and Ibtrozi, respectively. Meanwhile, Nuvation Bio demonstrated that its approved drug, Ibtrozi (taletrectinib), had a median duration of response (mDOR) of up to 50 months in untreated patients, demonstrating excellent long-term efficacy. Patients and physicians are expected to decide on prescriptions by comparing the adverse effect profiles and brain metastasis inhibitory effects of each drug in the future.

Trends and Market Outlook for Next-Generation Cancer Therapies

The various clinical results announced this time show that the field of targeted anticancer drugs is moving beyond simply delaying the growth of cancer to overcome resistance and maximize long-term survival. Drugs such as zoldonrasib and zidesamtinib offer new hope to patients who are resistant to existing treatments and are targeting markets with high unmet medical needs. In addition, as immune-oncology therapies using bispecific antibodies are becoming established as standard treatments, partnerships and technology transactions between large pharmaceutical companies and biotech companies are also expected to become more active. Industry experts say that if these new drugs reach the final approval stage, they have the potential to completely reshape the existing global anticancer drug market.